News articles about Denali Therapeutics (NASDAQ:DNLI) have trended somewhat negative on Monday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Denali Therapeutics earned a daily sentiment score of -0.05 on Accern’s scale. Accern also gave media coverage about the company an impact score of 47.1819544707044 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Zacks: Denali Therapeutics Inc (DNLI) Given Average Recommendation of “Buy” by Brokerages (americanbankingnews.com)
- Denali Therapeutics Inc (DNLI) Given $24.67 Consensus Target Price by Analysts (americanbankingnews.com)
- Here’s When You Can Buy Twitter’s Stock (finance.yahoo.com)
- Denali Therapeutics (DNLI) Issues Earnings Results (americanbankingnews.com)
- Denali Therapeutics Net Loss Widens, MoneyGram Net Swing to Loss (ticker.com)
Denali Therapeutics (NASDAQ:DNLI) opened at $21.34 on Monday. Denali Therapeutics has a 1-year low of $14.72 and a 1-year high of $25.79.
A number of equities research analysts recently weighed in on the stock. Evercore ISI assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They set an “outperform” rating and a $23.00 price target for the company. Morgan Stanley assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They set an “overweight” rating and a $25.00 price target for the company. JPMorgan Chase & Co. assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They set an “overweight” rating and a $24.00 price target for the company. Finally, Goldman Sachs assumed coverage on shares of Denali Therapeutics in a research note on Tuesday, January 2nd. They set a “neutral” rating for the company.
ILLEGAL ACTIVITY WARNING: “Denali Therapeutics (DNLI) Getting Somewhat Negative Press Coverage, Analysis Shows” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3301094/denali-therapeutics-dnli-getting-somewhat-negative-press-coverage-analysis-shows.html.
Denali Therapeutics Company Profile
Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.